PHF5A and nasal cavity and paranasal sinus carcinoma: The largest single-institution study of SMARCB1-deficient sinonasal carcinoma to date reported the outcomes of 19 consecutive patients with SMARCB1 (INI-1)-deficient sinonasal carcinoma treated at the MD Anderson Cancer Center.